Merkel Cell Carcinoma
A Clinically Oriented Mini-Review for Dermatologists.
Boostani M, Androus M, Williams A, Goldenberg A, Emri G, Wikonkál NM, Kiss N, Wong MK, Paragh G
DermatologyIn the feed 14 Aug 2026, published online 14 Aug 2026, issue 2026 Aug 14, added to PubMed 14 Aug 2026
Topics: Skin cancer & tumorsOther tumors & cystsDermatopathologyCancer drugs
Abstract
BACKGROUNDMerkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine malignancy with mortality rates exceeding melanoma at comparable stages. Its incidence is increasing worldwide, particularly among elderly, immunosuppressed, and fair-skinned individuals. Clinically, MCC often presents as a rapidly enlarging, asymptomatic nodule on sun-exposed skin, although atypical locations and morphologic variants may delay recognition.
SUMMARYThis clinically oriented mini-review summarizes current evidence most relevant to dermatologists regarding the epidemiology, risk factors, clinical presentation, histopathology, immunohistochemical diagnosis, staging, imaging, prognostic factors, circulating biomarkers, and treatment of MCC. Diagnosis relies on histopathology and immunohistochemistry, with cytokeratin 20 and Merkel cell polyomavirus (MCPyV)-related markers playing important roles in distinguishing MCC from other small round blue cell tumors. Imaging modalities, particularly 18F-fluorodeoxyglucose positron emission tomography/computed tomography, are essential for accurate staging and surveillance. Prognosis is influenced by tumor size, stage, immune status, age, and viral status. Emerging biomarkers such as circulating tumor DNA and MCPyV oncoprotein antibody titers are increasingly relevant for disease monitoring. Management is stage-specific and multidisciplinary, involving surgical excision, radiotherapy, and immune checkpoint inhibitors such as avelumab, pembrolizumab, nivolumab, and retifanlimab, which have improved outcomes in advanced disease.
KEY MESSAGESMCC is an uncommon but highly lethal skin cancer that requires early recognition, accurate staging, and multidisciplinary management. Dermatologists should be aware of both classic and atypical presentations to avoid delayed diagnosis. Recent advances in imaging, biomarkers, and immunotherapy have improved disease monitoring and treatment, but important global disparities remain in access to diagnostic tools and modern therapies.
Abstract from PubMed
PMID 42599837 · DOI 10.1159/000552053